The efficacy of sodium-dependent glucose co-transporter 2(SGLT2) inhibitors for pericardial fat in the type 2 diabetes patients
Not Applicable
- Conditions
- Type 2 diabetes patients with pericardial fat is more than 125 ml
- Registration Number
- JPRN-UMIN000020200
- Lead Sponsor
- ational Hospital Organization Takasaki General Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with decreased renal function. 2)Patient corresponding to the contraindications and careful administration of SGLT2 inhibitors. 3)Patients research investigator has determined to be inappropriate as a patient.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We administered the dapagliflozin to the patient, and observe the changes in the CT value of the amount and pericardial fat.
- Secondary Outcome Measures
Name Time Method We will observe changes in the subjective symptoms, objective findings, and clinical examination (blood biochemistry, electrocardiogram, ABI). In addition, we will evaluate the safety of such adverse events.